Acción BLRX BIOLINERX LTD.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas BioLineRx Ltd. Nasdaq

Acciones

BLRX

US09071M2052

Mercado cerrado - Nasdaq
Otros sitios de cotización
 22:30:00 28/05/2024 		Varia. Cinco días. Varia. 1 de enero.
0,719 USD +4,96 % Gráfico intradía de BioLineRx Ltd. +15,43 % -54,20 %
28/05 Transcript : BioLineRx Ltd., Q1 2024 Earnings Call, May 28, 2024
24/05 BioLineRx Ltd. Anuncia un resumen sobre los datos del estudio piloto del ensayo clínico combinado de fase 2 que evalúa la motixafortida en el cáncer de páncreas de primera línea en la Sociedad Americana de Oncología Clínica CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
BioLineRx : Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology
BioLineRx to Report First Quarter 2024 Results on May 28, 2024
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
BioLineRx : Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
BioLineRx : Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
BioLineRx Ltd. Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
BioLineRx Announces $6 Million Registered Direct Offering
BioLineRx Shares Fall After $6 Million Registered Direct Offering
BioLineRx : Form 20-F/A (Amendment No. 1
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
BioLineRx : Annual Report on Form 20-F FOR 2023
BioLineRx : Report of Periodic or Interim Report
BioLineRx : Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
BioLineRx Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (Bl-8040) Suitable for Large Scale Production
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción BLRX
  4. Acción BLRX
  5. Noticias BioLineRx Ltd.
  6. Otros idiomas
-40% Oferta por Tiempo Limitado: Nuestras suscripciones le guían hacia las mejores inversiones del mañana.
APROVÉCHELO AHORA